Quick context
TB-500
实验研究关注细胞迁移和创伤修复；尚未证实对人体有效。
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Back to all 64 profiles
Community/research information only未获 FDA/EMA 批准WADA
Community protocol · TB-500
TB-500: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: TB500 · Thymosin beta-4 fragment
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Community/research information only
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amount status
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: preclinical.
Timing
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycle/duration
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
复配计算器
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
复配计算器
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Synthetic thymosin beta-4-related fragment
TB-500 is classified as “Synthetic thymosin beta-4-related fragment”. 实验研究关注细胞迁移和创伤修复；尚未证实对人体有效。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
细胞迁移肽
这项研究考察某肽如何影响细胞向损伤部位的迁移,类似于工人们赶往施工现场。在实验室模型中测量细胞迁移的速度和程度。
肌动蛋白调节肽
这涉及对细胞骨架蛋白肌动蛋白的影响,该蛋白赋予细胞形态并使其能够移动,如同内部支架。研究人员在细胞培养模型中测量细胞迁移和创面闭合情况。
组织修复模型
研究人员在细胞或动物中使用受控的伤口或损伤模型,研究组织受损后愈合的速度和完整程度。测量指标通常包括伤口大小随时间的变化以及新组织形成的标志物,类似于每天拍照记录伤口愈合的速度。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
伤口愈合轶事
人们报告在使用某些肽后感觉伤口或肌腱问题愈合更快,通常没有对照组或客观测量。这类个人经历并不能证明实际的疗效或安全性。
恢复与损伤论坛
人们比较在使用不同修复肽时运动损伤后的个人恢复时间,通常基于主观疼痛量表。这类个体经历受许多其他因素影响,并不能证明疗效。
健身论坛
在这里,人们比较不同生长和修复肽之间的肌肉增长、力量提升和恢复时间,通常依据个人训练记录。商家和用户关于肌肉增长的说法属于个人经验之谈,而非对照研究结果。
Adverse effects and risk boundaries
- 许多所谓修复肽缺乏对照人体研究。未知全身效应、免疫反应、出血或血管影响，以及注射相关感染和污染仍是核心风险。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 妊娠、癌症、活动性感染、凝血障碍、计划手术及相关免疫疾病需要特别严格的专业评估或避免使用。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 未获批修复肽没有经过验证的监测方案。根据具体问题，临床表现、炎症征象、血常规、肝肾功能及凝血可能相关。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
临床前
缺乏经证实的人体疗效证据。
Published evidence
现有数据主要来自动物或细胞模型;缺乏可靠的人体有效性和安全性数据。
TB-500是一种与胸腺素β4相关的合成片段,而BPC-157则来源于另一种母体蛋白。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
未获 FDA/EMA 批准
没有 FDA 或 EMA 批准的药品；有效性与安全性尚未确立。
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA: 2026 peptide advisory review
- Primary/technical sourceWADA: 2026 prohibited list
- Primary/technical sourceFDA — TB-500 PCAC briefing document
- Community referenceTB-500 — Peptide Dosing Protocols